Wendy Martin Rios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wendy Martin Rios has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Fabiana Testa Moura de Carvalho Vicentini
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil
2 shared publications - Maíra Peres Ferreira
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
2 shared publications - Natália Floriano Paiva
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
2 shared publications - Amanda Marante Gimenez
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
1 shared publication - Anderson dos Santos Ramos
Center for Research in Inflammatory Diseases (CRID), Department of Pharmacology, Ribeirao Preto Medical School - University of Sao Paulo (USP), Ribeirão Preto, São Paulo, Brazil
1 shared publication - Camila Machado França de Almeida
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
1 shared publication
Latest Publications
- 6 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103985
Production of apoferritin/chitosan complex by Maillard reaction as a promising platform to enhance pDNA delivery
- 6 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103985
Production of apoferritin/chitosan complex by Maillard reaction as a promising platform to enhance pDNA delivery
- 28 November 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 206, 114589
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation
- 28 November 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 206, 114589
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation
- Open Access
- 19 May 2014
- Published by Springer Nature in BMC Microbiology
- Vol. 14 (1) , 128
Mycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages
Phospholipases C (PLCs) are virulence factors found in several bacteria. In Mycobacterium tuberculosis (Mtb) they exhibit cytotoxic effects on macrophages, but the mechanisms involved in PLC-induced cell death are not fully understood. It has been reported that induction of cell necrosis by virulent Mtb is coordinated by subversion of PGE2, an essential factor in cell membrane protection. Using two Mtb clinical isolates carrying genetic variations in PLC genes, we show that the isolate 97-1505, which bears plcA and plcB genes, is more resistant to alveolar macrophage microbicidal activity than the isolate 97-1200, which has all PLC genes deleted. The isolate 97-1505 also induced higher rates of alveolar macrophage necrosis, and likewise inhibited COX-2 expression and PGE2 production. To address the direct effect of mycobacterial PLC on cell necrosis and PGE2 inhibition, both isolates were treated with PLC inhibitors prior to macrophage infection. Interestingly, inhibition of PLCs affected the ability of the isolate 97-1505 to induce necrosis, leading to cell death rates similar to those induced by the isolate 97-1200. Finally, PGE2 production by Mtb 97-1505-infected macrophages was restored to levels similar to those produced by 97-1200-infected cells. Mycobacterium tuberculosis bearing PLCs genes induces alveolar macrophage necrosis, which is associated to subversion of PGE2 production.
- 19 May 2014
- Published by Springer Nature in BMC Microbiology
- Vol. 14 (1) , 128
Open AccessMycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages
Phospholipases C (PLCs) are virulence factors found in several bacteria. In Mycobacterium tuberculosis (Mtb) they exhibit cytotoxic effects on macrophages, but the mechanisms involved in PLC-induced cell death are not fully understood. It has been reported that induction of cell necrosis by virulent Mtb is coordinated by subversion of PGE2, an essential factor in cell membrane protection. Using two Mtb clinical isolates carrying genetic variations in PLC genes, we show that the isolate 97-1505, which bears plcA and plcB genes, is more resistant to alveolar macrophage microbicidal activity than the isolate 97-1200, which has all PLC genes deleted. The isolate 97-1505 also induced higher rates of alveolar macrophage necrosis, and likewise inhibited COX-2 expression and PGE2 production. To address the direct effect of mycobacterial PLC on cell necrosis and PGE2 inhibition, both isolates were treated with PLC inhibitors prior to macrophage infection. Interestingly, inhibition of PLCs affected the ability of the isolate 97-1505 to induce necrosis, leading to cell death rates similar to those induced by the isolate 97-1200. Finally, PGE2 production by Mtb 97-1505-infected macrophages was restored to levels similar to those produced by 97-1200-infected cells. Mycobacterium tuberculosis bearing PLCs genes induces alveolar macrophage necrosis, which is associated to subversion of PGE2 production.